Stephen Ayers
@meremrtl.bsky.social
Seeking Alpha analyst | MBA | BSN | RN
$ALDX "the option deal could signal that AbbVie anticipates that reproxalap could achieve global annual peak sales of $2 billion if it meets its clinical and market potential."
Aldeyra’s FDA Resubmission And AbbVie Option Revitalize Reproxalap’s Prospects (ALDX)
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ALDX stock a buy.
seekingalpha.com
November 14, 2024 at 5:26 PM
$ALDX "the option deal could signal that AbbVie anticipates that reproxalap could achieve global annual peak sales of $2 billion if it meets its clinical and market potential."